These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33088577)

  • 41. [Market surveillance and control of substandard, falsified and unregistered medicines: integrative reviewVigilancia y control de medicamentos subestándar, falsificados y no registrados: una revisión integral].
    Martins MAF; Scherer MDDA; Lucchese G
    Rev Panam Salud Publica; 2022; 46():e36. PubMed ID: 35520020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of combined screening methods for rapid detection of falsified and/or substandard medicines in the absence of a confirmatory method.
    Opuni KF; Nettey H; Larbi MA; Amartey SNA; Nti G; Dzidonu A; Owusu-Danso P; Owusu NA; Nyarko AK
    Malar J; 2019 Dec; 18(1):403. PubMed ID: 31805937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating Low-Cost Optical Spectrometers for the Detection of Simulated Substandard and Falsified Medicines.
    Wang W; Keller MD; Baughman T; Wilson BK
    Appl Spectrosc; 2020 Mar; 74(3):323-333. PubMed ID: 31617368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The quality of medical products for cardiovascular diseases: a gap in global cardiac care.
    Do NT; Bellingham K; Newton PN; Caillet C
    BMJ Glob Health; 2021 Sep; 6(9):. PubMed ID: 34521627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey.
    Fitsum Y; Werede A; Mahmud Saleh A; Tesfamariam EH; Magombo F; Misghina F; Yemane H; Bahta I; Abraham L; Bahta M; Debesai M; Tesfagaber M; Ghirmai M; Tesfamariam S; Russom M
    Ther Adv Drug Saf; 2023; 14():20420986231213713. PubMed ID: 38107771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The quality of veterinary medicines and their implications for One Health.
    Vidhamaly V; Bellingham K; Newton PN; Caillet C
    BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35918072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.
    Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
    Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study.
    Higgins CR; Kobia B; Ozawa S
    PLoS One; 2023; 18(1):e0268661. PubMed ID: 36652447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Global landscape assessment of screening technologies for medicine quality assurance: stakeholder perceptions and practices from ten countries.
    Roth L; Nalim A; Turesson B; Krech L
    Global Health; 2018 Apr; 14(1):43. PubMed ID: 29695278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern Malawi.
    Khuluza F; Kigera S; Heide L
    Am J Trop Med Hyg; 2017 May; 96(5):1124-1135. PubMed ID: 28219993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Falsification of medical products: criminal law mechanism combating threats to public health.
    Gutorova N; Zhytnyi O; Soloviov O
    Wiad Lek; 2019; 72(5 cz 1):856-861. PubMed ID: 31175785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study.
    Ozawa S; Evans DR; Higgins CR; Laing SK; Awor P
    Malar J; 2019 Jan; 18(1):5. PubMed ID: 30626380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries.
    Hauk C; Hagen N; Heide L
    Am J Trop Med Hyg; 2021 Mar; 104(5):1936-1945. PubMed ID: 33788775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country.
    Khurelbat D; Dorj G; Sunderland B; Sanjjav T; Bayarsaikhan E; Damdinjav D; Dorj G; Jigjidsuren A; Lkhagvasuren O; Erdenetsetseg B
    BMC Public Health; 2020 May; 20(1):743. PubMed ID: 32434489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Harmonization of medical products regulation: a key factor for improving regulatory capacity in the East African Community.
    Ndomondo-Sigonda M; Miot J; Naidoo S; Masota NE; Ng'andu B; Ngum N; Kaale E
    BMC Public Health; 2021 Jan; 21(1):187. PubMed ID: 33478421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Situation analysis on the regulation of nanomedicines in Southern Africa.
    Mudyiwenyama LG; Khoza S; Dube A
    Front Med (Lausanne); 2023; 10():1098830. PubMed ID: 37153083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Establishment of the African Medicines Agency: progress, challenges and regulatory readiness.
    Ncube BM; Dube A; Ward K
    J Pharm Policy Pract; 2021 Mar; 14(1):29. PubMed ID: 33685518
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.